The brief
- Zevaskyn approved by FDA April 2025, the first cell-based gene therapy for RDEB wounds.
- Q2 2026 Zevaskyn revenue $11.4M (+31% QoQ); 12 patient treatments since launch.
- Manufacturing yield is the bottleneck: two treatments so far could not be billed.
